Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 27;8(4):002546.
doi: 10.12890/2021_002546. eCollection 2021.

Gemfibrozil-Induced Polyuria

Ashraf Oe Ahmed  1 , Edmond Okotcha  2 , Abdul-Hussein Saad  2
Affiliations

Gemfibrozil-Induced Polyuria

Ashraf Oe Ahmed et al. Eur J Case Rep Intern Med. .

Abstract

Gemfibrozil is a lipid-regulating agent used mainly to treat patients with hypertriglyceridaemia, especially those at risk for acute pancreatitis. Like any other pharmacological agent, gemfibrozil has known adverse effects, mainly gastrointestinal, such as cholelithiasis, gallstones, elevated transaminase, and other non-specific symptoms including dyspepsia, nausea and vomiting. Other reported adverse reactions are dizziness and vertigo, myopathy and rhabdomyolysis, angioedema, urticaria and rash. As far as we knew, gemfibrozil does not have urinary tract adverse reactions. In this report, we present a case of polyuria secondary to gemfibrozil with a score of 9 on the Naranjo scale, and a literature review.

Learning points: Gemfibrozil has known, mainly gastrointestinal, adverse effects.We aim to increase awareness of the urinary side effects of gemfibrozil so unnecessary investigations can be avoided.

Keywords: Gemfibrozil; anti-hyperlipidaemic; polyuria; urinary side effects.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interests: The Authors declare that there are no competing interests.

References

    1. Hendrani AD, Adesiyun T, Quispe R, Jones SR, Stone NJ, Blumenthal RS, et al. Dyslipidemia management in primary prevention of cardiovascular disease: current guidelines and strategies. World J Cardiol. 2016;8(2):201–210. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766270/pdf/WJC-8-201.pdf. - PMC - PubMed
    1. Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to statins: mechanisms and management. Diabetes Care. 2013;36(Suppl 2):S325–S330. https://care.diabetesjournals.org/content/diacare/36/Supplement_2/S325.f.... - PMC - PubMed
    1. Ito MK. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Atherosclerosis. 2015;242(2):647–656. - PubMed
    1. Bussière-Côté S, Omlin T, de Càssia Pinheiro E, Weber J-M. Gemfibrozil disrupts the metabolism of circulating lipids in bobwhite quails. Comp Biochem Physiol Toxicol Pharmacol. 2016;179:137–143. doi: 10.1016/j.cbpc.2015.09.011. - DOI - PubMed
    1. Ghosh A, Rangasamy SB, Modi KK, Pahan K. Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis. J Neurochem. 2017;141(3):423–435. doi: 10.1111/jnc.13987. - DOI - PMC - PubMed

LinkOut - more resources